Cargando…

Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19

BACKGROUND: Early intubation versus use of conventional or high-flow nasal cannula oxygen therapy (COT/HFNC), continuous positive airway pressure (CPAP), and non-invasive ventilation (NIV) has been debated throughout the COVID-19 pandemic. Our centre followed a stepwise approach, in concordance with...

Descripción completa

Detalles Bibliográficos
Autores principales: Matthes, Sandhya, Holl, Johannes, Randerath, Johannes, Treml, Marcel, Bockover, Michael, Herkenrath, Simon, Hagmeyer, Lars, Knoch, Johannes, Oesterlee, Ulrike, Sofianos, Georgios, Randerath, Winfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614468/
https://www.ncbi.nlm.nih.gov/pubmed/37669641
http://dx.doi.org/10.1159/000533522
_version_ 1785129036120326144
author Matthes, Sandhya
Holl, Johannes
Randerath, Johannes
Treml, Marcel
Bockover, Michael
Herkenrath, Simon
Hagmeyer, Lars
Knoch, Johannes
Oesterlee, Ulrike
Sofianos, Georgios
Randerath, Winfried
author_facet Matthes, Sandhya
Holl, Johannes
Randerath, Johannes
Treml, Marcel
Bockover, Michael
Herkenrath, Simon
Hagmeyer, Lars
Knoch, Johannes
Oesterlee, Ulrike
Sofianos, Georgios
Randerath, Winfried
author_sort Matthes, Sandhya
collection PubMed
description BACKGROUND: Early intubation versus use of conventional or high-flow nasal cannula oxygen therapy (COT/HFNC), continuous positive airway pressure (CPAP), and non-invasive ventilation (NIV) has been debated throughout the COVID-19 pandemic. Our centre followed a stepwise approach, in concordance with German national guidelines, escalating non-invasive modalities prior to invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), rather than early or late intubation. OBJECTIVES: The aims of the study were to investigate the real-life usage of these modalities and analyse patient characteristics and survival. METHOD: A retrospective monocentric observation was conducted of all consecutive COVID-19 hospital admissions between March 2020 and December 2021 at a university-affiliated pulmonary centre in Germany. Anthropometric data, therapy, and survival status were descriptively analysed. RESULTS: From 1,052 COVID-19-related admissions, 835 patients were included (54% male, median 58 years). Maximum therapy was as follows: 34% (n = 284) no therapy, 40% (n = 337) COT, 3% (n = 22) HFNC, 9% (n = 73) CPAP, 7% (n = 56) NIV, 4% (n = 34) IMV, and 3% (n = 29) ECMO. Of 551 patients treated with at least COT, 12.3% required intubation. Overall, 183 patients required intensive unit care, and 106 (13%) died. Of the 68 patients who received IMV/ECMO, 48 died (74%). The strategy for non-pharmacological therapy was individual but remained consistent throughout the studied period. CONCLUSIONS: This study provides valuable insight into COVID-19 care in Germany and shows how the majority of patients could be treated with the maximum treatment required according to disease severity following the national algorithm. Escalation of therapy modality is interlinked with disease severity and thus associated with mortality.
format Online
Article
Text
id pubmed-10614468
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-106144682023-10-31 Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19 Matthes, Sandhya Holl, Johannes Randerath, Johannes Treml, Marcel Bockover, Michael Herkenrath, Simon Hagmeyer, Lars Knoch, Johannes Oesterlee, Ulrike Sofianos, Georgios Randerath, Winfried Respiration Clinical Investigations BACKGROUND: Early intubation versus use of conventional or high-flow nasal cannula oxygen therapy (COT/HFNC), continuous positive airway pressure (CPAP), and non-invasive ventilation (NIV) has been debated throughout the COVID-19 pandemic. Our centre followed a stepwise approach, in concordance with German national guidelines, escalating non-invasive modalities prior to invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO), rather than early or late intubation. OBJECTIVES: The aims of the study were to investigate the real-life usage of these modalities and analyse patient characteristics and survival. METHOD: A retrospective monocentric observation was conducted of all consecutive COVID-19 hospital admissions between March 2020 and December 2021 at a university-affiliated pulmonary centre in Germany. Anthropometric data, therapy, and survival status were descriptively analysed. RESULTS: From 1,052 COVID-19-related admissions, 835 patients were included (54% male, median 58 years). Maximum therapy was as follows: 34% (n = 284) no therapy, 40% (n = 337) COT, 3% (n = 22) HFNC, 9% (n = 73) CPAP, 7% (n = 56) NIV, 4% (n = 34) IMV, and 3% (n = 29) ECMO. Of 551 patients treated with at least COT, 12.3% required intubation. Overall, 183 patients required intensive unit care, and 106 (13%) died. Of the 68 patients who received IMV/ECMO, 48 died (74%). The strategy for non-pharmacological therapy was individual but remained consistent throughout the studied period. CONCLUSIONS: This study provides valuable insight into COVID-19 care in Germany and shows how the majority of patients could be treated with the maximum treatment required according to disease severity following the national algorithm. Escalation of therapy modality is interlinked with disease severity and thus associated with mortality. S. Karger AG 2023-09-05 2023-09 /pmc/articles/PMC10614468/ /pubmed/37669641 http://dx.doi.org/10.1159/000533522 Text en © 2023 The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Clinical Investigations
Matthes, Sandhya
Holl, Johannes
Randerath, Johannes
Treml, Marcel
Bockover, Michael
Herkenrath, Simon
Hagmeyer, Lars
Knoch, Johannes
Oesterlee, Ulrike
Sofianos, Georgios
Randerath, Winfried
Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19
title Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19
title_full Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19
title_fullStr Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19
title_full_unstemmed Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19
title_short Analysis of an Individualised Stepwise Approach to Non-Pharmacological Therapy in COVID-19
title_sort analysis of an individualised stepwise approach to non-pharmacological therapy in covid-19
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614468/
https://www.ncbi.nlm.nih.gov/pubmed/37669641
http://dx.doi.org/10.1159/000533522
work_keys_str_mv AT matthessandhya analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19
AT holljohannes analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19
AT randerathjohannes analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19
AT tremlmarcel analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19
AT bockovermichael analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19
AT herkenrathsimon analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19
AT hagmeyerlars analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19
AT knochjohannes analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19
AT oesterleeulrike analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19
AT sofianosgeorgios analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19
AT randerathwinfried analysisofanindividualisedstepwiseapproachtononpharmacologicaltherapyincovid19